1126.8000 0.40 (0.04%)
NSE Jul 03, 2026 15:31 PM
Volume: 96,579
 

1126.80
0.04%
Geojit BNP Paribas
Strides reported its Q2FY22 revenue at Rs. 721cr, (4.8% QoQ, -9% YoY), enabled by a bounce back in the other regulated markets which was partially offset by an underperformance in the US markets. US markets (34% of total revenues) witnessed a 17% QoQ/-38% YoY...
Strides Pharma has gained 25.10% in the last 6 Months
More from Strides Pharma Science Ltd.
Recommended